Today, we're joined by Dr. Tatiana Novobrantseva, the Chief Scientific Officer at NextPoint Therapeutics, a clinical-stage biotech company pioneering precision immuno-oncology therapies targeting the novel HHLA2 (B7-H7) pathway.Tatiana brings over two decades of expertise in immunology, cancer, immuno-oncology, autoimmunity, and fibrosis. She co-founded Verseau Therapeutics in 2017, serving as CSO and advancing novel immunotherapies that stimulate macrophage repolarization to initiate anti-cancer immune responses. Prior to that, she led oncology discovery and development projects at Moderna as Chief Scientific Officer, Immuno-Oncology Research.At NextPoint, Tatiana is leading the development of therapies targeting the B7-H7 immune checkpoint pathway, aiming to reactivate exhausted T and NK cells in solid tumors. This approach offers a promising alternative for patients who have not responded to traditional PD-1/CTLA-4 therapies.Dr. Novobrantseva earned her Ph.D. in immunology from the University of Cologne in Germany and completed postdoctoral research at Harvard Medical School in the laboratory of Dr. Klaus Rajewsky, focusing on B cell immunology and autoimmunity